The utility of a methylation panel in the assessment of clinical response to radiofrequency ablation for Barrett's esophagus
Open Access
- 22 July 2020
- journal article
- research article
- Published by Elsevier BV in EBioMedicine
- Vol. 58, 102877
- https://doi.org/10.1016/j.ebiom.2020.102877
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagusGut, 2013
- DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett's EsophagusClinical Cancer Research, 2013
- The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysisGut, 2011
- Durability of Radiofrequency Ablation in Barrett's Esophagus With DysplasiaGastroenterology, 2011
- Radiofrequency Ablation in Barrett's Esophagus with DysplasiaThe New England Journal of Medicine, 2009
- Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysisGastrointestinal Endoscopy, 2008
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003
- The Z-line appearance and prevalence of intestinal metaplasia among patients without symptoms or endoscopical signs indicating gastroesophageal refluxSurgical Endoscopy, 2001
- Gastric Cardia Intestinal Metaplasia: Biopsy Follow-Up of 85 PatientsLaboratory Investigation, 2000
- Prevalence of metaplasia at the gastro-oesophageal junctionThe Lancet, 1994